ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
- 1 September 2021
- journal article
- aggressive b-cell-lymphoma
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21, S378-S379
- https://doi.org/10.1016/s2152-2650(21)01863-2